Next Article in Journal
The Roles of DNA Topoisomerase IIβ in Transcription
Next Article in Special Issue
Role of Arginine 117 in Substrate Recognition by Human Cytochrome P450 2J2
Previous Article in Journal
Cynoglossus semilaevis Rspo3 Regulates Embryo Development by Inhibiting the Wnt/β-Catenin Signaling Pathway
Previous Article in Special Issue
Effect of Nicotine on CYP2B1 Expression in a Glioma Animal Model and Analysis of CYP2B6 Expression in Pediatric Gliomas
Open AccessReview

Regulation of CYP2J2 and EET Levels in Cardiac Disease and Diabetes

1
Department of Medicinal Chemistry, University of Washington, Seattle, WA 98101, USA
2
Cardiovascular Health Research Unit, University of Washington, Seattle, WA 98195, USA
3
Department of Medicine, University of Washington, Seattle, WA 98195, USA
4
Division of Cardiology, University of Washington, Seattle, WA 98195, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(7), 1916; https://doi.org/10.3390/ijms19071916
Received: 29 April 2018 / Revised: 24 June 2018 / Accepted: 25 June 2018 / Published: 29 June 2018
(This article belongs to the Special Issue Cytochromes P450: Drug Metabolism and Bioactivation)
Cytochrome P450 2J2 (CYP2J2) is a known arachidonic acid (AA) epoxygenase that mediates the formation of four bioactive regioisomers of cis-epoxyeicosatrienoic acids (EETs). Although its expression in the liver is low, CYP2J2 is mainly observed in extrahepatic tissues, including the small intestine, pancreas, lung, and heart. Changes in CYP2J2 levels or activity by xenobiotics, disease states, or polymorphisms are proposed to lead to various organ dysfunctions. Several studies have investigated the regulation of CYP2J2 and EET formation in various cell lines and have demonstrated that such regulation is tissue-dependent. In addition, studies linking CYP2J2 polymorphisms to the risk of developing cardiovascular disease (CVD) yielded contradictory results. This review will focus on the mechanisms of regulation of CYP2J2 by inducers, inhibitors, and oxidative stress modeling certain disease states in various cell lines and tissues. The implication of CYP2J2 expression, polymorphisms, activity and, as a result, EET levels in the pathophysiology of diabetes and CVD will also be discussed. View Full-Text
Keywords: CYP2J2; epoxyeicosatrienoic acids; hypertension; cardiovascular disease; diabetes CYP2J2; epoxyeicosatrienoic acids; hypertension; cardiovascular disease; diabetes
Show Figures

Scheme 1

MDPI and ACS Style

Aliwarga, T.; Evangelista, E.A.; Sotoodehnia, N.; Lemaitre, R.N.; Totah, R.A. Regulation of CYP2J2 and EET Levels in Cardiac Disease and Diabetes. Int. J. Mol. Sci. 2018, 19, 1916.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop